Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients
Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 1995-10, Vol.6 (8), p.755-758 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 758 |
---|---|
container_issue | 8 |
container_start_page | 755 |
container_title | Annals of oncology |
container_volume | 6 |
creator | Chang, J. Sharpe, J. C. A'Hern, R. P. Fisher, C. Blake, P. Shepherd, J. Gore, M. E. |
description | Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy |
doi_str_mv | 10.1093/oxfordjournals.annonc.a059312 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77775636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77775636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</originalsourceid><addsrcrecordid>eNpVkFFrFDEUhYModW39CcI8aJ86azJ3kkwEH2SxtlixoBXxJdzJJDp1JtkmM0v7703ZYcG8XMg5J_fkI-QNo2tGFbwN9y7E7jbM0eOQ1uh98GaNlCtg1ROyYlyosqE1e0pWVFVQSg71c_IipVtKqVCVOiJHDW8UZWxFbjYYTe9DyiOMWARXTH9sEXYYH94Vl970nfXGnhXbGH5nW5_OiilanEbrpwJ9V6Q57vodDo_RLU59vk8n5JnL5ezLZR6Tm_OP3zcX5dXXT5ebD1elqetqKisqc-3WtI3i3BgjbCclMtc41xmOxjELNSoDKBHaRkBrFDijpLCu7VoFx-R0_25udzfbNOmxT8YOA3ob5qRlPlyAyMb3e6OJIaVond7Gfsx_1IzqR6z6f6x6j1UvWHP-1bJobkfbHdILx6y_XnRMBgcXMZNLBxsIBZRDtpV7W58me3-QMf7VQoLk-uLnL_1ZifrbF7jWP-Af4BqaNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77775636</pqid></control><display><type>article</type><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</creator><creatorcontrib>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</creatorcontrib><description>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/oxfordjournals.annonc.a059312</identifier><identifier>PMID: 8589011</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinosarcoma - epidemiology ; Carcinosarcoma - pathology ; Carcinosarcoma - therapy ; carcinosarcoma ovary ; Combined Modality Therapy ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Incidence ; management ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Ovarian Neoplasms - epidemiology ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Prognosis ; prognostic factors ; Retrospective Studies ; Survival Rate ; Tumors</subject><ispartof>Annals of oncology, 1995-10, Vol.6 (8), p.755-758</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</citedby><cites>FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3693053$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8589011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Sharpe, J. C.</creatorcontrib><creatorcontrib>A'Hern, R. P.</creatorcontrib><creatorcontrib>Fisher, C.</creatorcontrib><creatorcontrib>Blake, P.</creatorcontrib><creatorcontrib>Shepherd, J.</creatorcontrib><creatorcontrib>Gore, M. E.</creatorcontrib><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinosarcoma - epidemiology</subject><subject>Carcinosarcoma - pathology</subject><subject>Carcinosarcoma - therapy</subject><subject>carcinosarcoma ovary</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Incidence</subject><subject>management</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkFFrFDEUhYModW39CcI8aJ86azJ3kkwEH2SxtlixoBXxJdzJJDp1JtkmM0v7703ZYcG8XMg5J_fkI-QNo2tGFbwN9y7E7jbM0eOQ1uh98GaNlCtg1ROyYlyosqE1e0pWVFVQSg71c_IipVtKqVCVOiJHDW8UZWxFbjYYTe9DyiOMWARXTH9sEXYYH94Vl970nfXGnhXbGH5nW5_OiilanEbrpwJ9V6Q57vodDo_RLU59vk8n5JnL5ezLZR6Tm_OP3zcX5dXXT5ebD1elqetqKisqc-3WtI3i3BgjbCclMtc41xmOxjELNSoDKBHaRkBrFDijpLCu7VoFx-R0_25udzfbNOmxT8YOA3ob5qRlPlyAyMb3e6OJIaVond7Gfsx_1IzqR6z6f6x6j1UvWHP-1bJobkfbHdILx6y_XnRMBgcXMZNLBxsIBZRDtpV7W58me3-QMf7VQoLk-uLnL_1ZifrbF7jWP-Af4BqaNA</recordid><startdate>19951001</startdate><enddate>19951001</enddate><creator>Chang, J.</creator><creator>Sharpe, J. C.</creator><creator>A'Hern, R. P.</creator><creator>Fisher, C.</creator><creator>Blake, P.</creator><creator>Shepherd, J.</creator><creator>Gore, M. E.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951001</creationdate><title>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</title><author>Chang, J. ; Sharpe, J. C. ; A'Hern, R. P. ; Fisher, C. ; Blake, P. ; Shepherd, J. ; Gore, M. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-207059bcb8955ccc6ed77a1f8ffdc5acf1e34a9c3a7a3b863bc93fc976efbdb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinosarcoma - epidemiology</topic><topic>Carcinosarcoma - pathology</topic><topic>Carcinosarcoma - therapy</topic><topic>carcinosarcoma ovary</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Incidence</topic><topic>management</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Sharpe, J. C.</creatorcontrib><creatorcontrib>A'Hern, R. P.</creatorcontrib><creatorcontrib>Fisher, C.</creatorcontrib><creatorcontrib>Blake, P.</creatorcontrib><creatorcontrib>Shepherd, J.</creatorcontrib><creatorcontrib>Gore, M. E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, J.</au><au>Sharpe, J. C.</au><au>A'Hern, R. P.</au><au>Fisher, C.</au><au>Blake, P.</au><au>Shepherd, J.</au><au>Gore, M. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>1995-10-01</date><risdate>1995</risdate><volume>6</volume><issue>8</issue><spage>755</spage><epage>758</epage><pages>755-758</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Carcinosarcomas (also known as malignant mixed mullerian tumours) are rare malignant neoplasms that histologically contain both epithelial and stromal components Methods and materials: All cases of carcinosarcoma of the ovary presenting to the Royal Marsden Hospital from January 1975 to August 1993 were retrospectively analysed and the histological sections reviewed Results: There were 37 cases of carcinosarcoma of the ovary representing 1.12% of the ovarian neoplasms seen at this institution. The median age of presentation was 65 years (range 26–85 years) and 70% of patients had advanced disease (FIGO stage III and IV). Clinical features at presentation were similar to those encountered in patients with epithelial ovarian cancer. The overall median survival was 247 days with 40% 1-year survival and 6% 5-year survival for all stages. Early FIGO stage was the only independent prognostic factor for survival. Histology (homologous/ heterologous subtypes; grade, type or percentage of the epithelial component) had no significant impact on survival. Adjuvant radiotherapy may have a role and single agent platinum compounds are active, giving a response rate of 35% Conclusions: The management of this tumour is difficult and randomised trials are needed to accrue sufficient patient numbers to demonstrate optimal therapy</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>8589011</pmid><doi>10.1093/oxfordjournals.annonc.a059312</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0923-7534 |
ispartof | Annals of oncology, 1995-10, Vol.6 (8), p.755-758 |
issn | 0923-7534 1569-8041 |
language | eng |
recordid | cdi_proquest_miscellaneous_77775636 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinosarcoma - epidemiology Carcinosarcoma - pathology Carcinosarcoma - therapy carcinosarcoma ovary Combined Modality Therapy Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Incidence management Medical sciences Middle Aged Multivariate Analysis Neoplasm Staging Ovarian Neoplasms - epidemiology Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Prognosis prognostic factors Retrospective Studies Survival Rate Tumors |
title | Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A30%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carcinosarcoma%20of%20the%20ovary:%20Incidence,%20prognosis,%20treatment%20and%20survival%20of%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Chang,%20J.&rft.date=1995-10-01&rft.volume=6&rft.issue=8&rft.spage=755&rft.epage=758&rft.pages=755-758&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/oxfordjournals.annonc.a059312&rft_dat=%3Cproquest_cross%3E77775636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77775636&rft_id=info:pmid/8589011&rfr_iscdi=true |